4SC AG Logo

4SC AG

Developing small-molecule epigenetic drugs for high-need cancer indications.

VSC | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C40
LEI:
391200QOKN7LGVP0RQ86
Country:
Germany
Address:
Fraunhoferstr. 22, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

4SC AG is a clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs for cancer treatment. The company focuses on oncology indications with high unmet medical needs. Its core research and development strategy targets key epigenetic mechanisms involved in cancer development and progression, with a particular emphasis on histone deacetylase (HDAC) inhibitors. The company's product pipeline comprises drug programs in various stages of clinical development, aiming to offer patients more effective and better-tolerated therapeutic options to improve their quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.4 KB
2024-08-08 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 101.6 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.3 KB
2023-08-10 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 100.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-11-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 174.5 KB
2021-12-01 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-12-01 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2021-05-26 00:00
Annual Report
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-02-04 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2021 bis zum 30.06.2021
German 6.4 KB
2021-02-04 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2020 bis zum 31.12.2020
German 6.4 KB
2020-05-08 00:00
Business and Financial Review
Q1 statement / Q1 financial report 2020
English 489.3 KB

Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 4SC AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 4SC AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.